Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) released its quarterly earnings results on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05, Zacks reports.

Centessa Pharmaceuticals Trading Down 4.2 %

NASDAQ CNTA traded down $0.76 during trading hours on Thursday, hitting $17.32. 217,234 shares of the company were exchanged, compared to its average volume of 401,507. The stock has a market cap of $1.96 billion, a PE ratio of -11.82 and a beta of 1.47. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average price of $15.81 and a 200 day moving average price of $12.03. Centessa Pharmaceuticals has a 52 week low of $5.58 and a 52 week high of $18.74.

Insider Activity

In related news, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.53, for a total transaction of $909,150.00. Following the completion of the transaction, the chief executive officer now directly owns 721,924 shares of the company’s stock, valued at approximately $11,933,403.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.53, for a total value of $909,150.00. Following the transaction, the chief executive officer now owns 721,924 shares of the company’s stock, valued at $11,933,403.72. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the sale, the insider now owns 183,266 shares of the company’s stock, valued at $2,818,631.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 325,031 shares of company stock valued at $5,213,043. 11.59% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Oppenheimer restated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Finally, Guggenheim raised their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.